<p> <i>For data sources see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0033317#pone.0033317.s001" target="_blank">Table S1</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0033317#pone.0033317.s002" target="_blank">Table S2</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0033317#pone.0033317.s003" target="_blank">Table S3</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0033317#pone.0033317.s004" target="_blank">Table S4</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0033317#pone.0033317.s005" target="_blank">Table S5</a>.</i></p
1<p>(<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0051402#pone.0051402-Widm...
<p>* All data are expressed as number (%)</p><p>Characteristics of the study populations<sup><a href...
<p>*<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0105969#pone-0105969-t003"...
<p>Estimates of population size, disease rates, case-fatality rates, and associated costs<sup><a hre...
<p>When treatment efficacy increases, some of the decrease in disease prevalence is lost due to a de...
<p>Exp1: Expected value from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0...
<p>This graph shows the proportion of articles by discipline that make some use of data as part of t...
<p>*Percentages are based on all randomised patients; FAS, full analysis set; PPAS3m, per protocol a...
<p>Descriptive statistics for study variables and cancer prevalence<a href="http://www.plosone.org/a...
<p>The column ‘number infected’ shows the possible range of actual infections, ranging from the numb...
<p>* Values are the number of patients/number of controls.</p><p>Demographic distribution of the ind...
Mean disease prevalence after 10 years of 30 simulation runs for different population sizes of 10,00...
<p>Reported number and prevalence (per 10,000 of the total population) of clinical cases.</p
<p>Only countries with a population of over 10 million are listed. Dashes indicate that these infect...
<p>Prevalence rates of chronic diseases and syndromes in the study population by sex.</p
1<p>(<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0051402#pone.0051402-Widm...
<p>* All data are expressed as number (%)</p><p>Characteristics of the study populations<sup><a href...
<p>*<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0105969#pone-0105969-t003"...
<p>Estimates of population size, disease rates, case-fatality rates, and associated costs<sup><a hre...
<p>When treatment efficacy increases, some of the decrease in disease prevalence is lost due to a de...
<p>Exp1: Expected value from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0...
<p>This graph shows the proportion of articles by discipline that make some use of data as part of t...
<p>*Percentages are based on all randomised patients; FAS, full analysis set; PPAS3m, per protocol a...
<p>Descriptive statistics for study variables and cancer prevalence<a href="http://www.plosone.org/a...
<p>The column ‘number infected’ shows the possible range of actual infections, ranging from the numb...
<p>* Values are the number of patients/number of controls.</p><p>Demographic distribution of the ind...
Mean disease prevalence after 10 years of 30 simulation runs for different population sizes of 10,00...
<p>Reported number and prevalence (per 10,000 of the total population) of clinical cases.</p
<p>Only countries with a population of over 10 million are listed. Dashes indicate that these infect...
<p>Prevalence rates of chronic diseases and syndromes in the study population by sex.</p
1<p>(<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0051402#pone.0051402-Widm...
<p>* All data are expressed as number (%)</p><p>Characteristics of the study populations<sup><a href...
<p>*<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0105969#pone-0105969-t003"...